UK regulator calls for review of reactions in eyes to Sanofi asthma drug
Reuters
Published Nov 29, 2022 14:55
Updated Nov 29, 2022 15:53
(Reuters) -Britain's medicines regulator said on Tuesday that any new or worsening reactions in patients' eyes arising from use of Sanofi (EPA:SASY)'s best-selling asthma and eczema drug Dupixent should be promptly reviewed by healthcare professionals.
The UK's Medicines and Healthcare products Regulatory Agency said most ocular reactions seen with the drug are mild and can be managed.
European and U.S. health regulators have listed conjunctivitis, an eye irritation that can cause redness and discomfort, as a side effect of Dupixent.
The eczema and asthma drug generated 2021 sales of 5.25 billion euros ($5.43 billion), accounting for 13.9% of group revenues and making it Sanofi's biggest-selling product.
The French drugmaker expects the treatment to generate up to 13 billion euros in sales in its best year as it seeks to widen its use across a number of inflammatory conditions.
Sanofi did not have an immediate comment.
($1 = 0.9677 euros)
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.